Study of a new drug for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have extensive-stage small cell lung cancer, meaning the cancer has spread beyond one lung.
- You have received exactly one prior treatment for SCLC that included a platinum-based drug, with at least 2 cycles, and it has been at least 30 days since that treatment ended and the cancer grew.
- You must have at least one tumor that can be measured on a scan.
- Your cancer must have grown or spread after your most recent treatment, as shown on imaging.
- You must be physically able to care for yourself (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new investigational drug (IBB0979) to the standard chemotherapy topotecan helps people with small cell lung cancer whose cancer has come back after earlier treatment. The goal is to see if the combination is more effective than topotecan alone.
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.